BSX — BOSTON SCIENTIFIC CORP
Health Care · Medical Devices
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying BSX?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 6 tracked investors who changed their BSX position last quarter, 5 bought and 1 sold (83% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime). 5 congressional purchases, 2 sales disclosed in the last 6 months.
- +5 tracked investors added or increased positions last quarter (Paul Tudor Jones, Izzy Englander, Ken Griffin, …)
- +7 tracked investors reported holding BSX at their latest filing
- +Macro Health is 52/100 in a Squeeze regime — historically acceptable for Health Caresource
- +5 congressional purchases disclosed in the last 6 months
- −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.
About BOSTON SCIENTIFIC CORP (BSX)
BOSTON SCIENTIFIC CORP (BSX) appears in the most recent 13F filings of 7 tracked institutional investors. BOSTON SCIENTIFIC CORP is classified in the Health Care sector (Medical Devices industry). The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $1.2B. Across recent filings, tracked investors recorded 12 new positions, 0 increased, 2 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in BSX
How many top investors track BSX
Several tracked investors have exposure.
BSX Ownership Composition
How BOSTON SCIENTIFIC CORP is held across tracked investor types, based on reported 13F positions.
- Other74.0%
- Hedge Funds26.0%
Tracked investors reporting BSX
- Izzy EnglanderMar 31, 2026Millennium ManagementShares5.3MValue$303.5M% Portfolio0.13%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares6.7MValue$422.9M% Portfolio0.07%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares5.8MValue$365.9M% Portfolio0.47%
- Andreas HalvorsenDec 31, 2025Viking Global InvestorsShares2.5MValue$239.3M% Portfolio0.64%
- Paul Tudor JonesMar 31, 2026Tudor Investment CorpShares1.1MValue$66.4M% Portfolio0.12%
- Steve MandelMar 31, 2026Lone Pine CapitalShares104.7KValue$6.6M% Portfolio0.05%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares77KValue$4.8M% Portfolio0.02%
Recent activity
- $74.9MFeb 17, 2026
- $66.4MMay 15, 2026
- $1.2BFeb 17, 2026
- $303.5MMay 15, 2026
- New$273.9MFeb 17, 2026
- New$422.9MMay 15, 2026
- $239.3MFeb 17, 2026
- New$19.2MFeb 17, 2026
- New$6.6MMay 15, 2026
- New$365.9MMay 15, 2026
- Reduced$4.8M(-17.87%)May 15, 2026
- Reduced$8.9M(-41.31%)Feb 13, 2026
- New$977.4MNov 14, 2025
- New$15.6MNov 13, 2025
Frequently asked questions
- How many institutional investors hold BSX?
- 7 tracked institutional investors disclosed a position in BSX (BOSTON SCIENTIFIC CORP) in their most recent 13F filing.
- Who is the largest institutional holder of BSX?
- Izzy Englander, Millennium Management, holds the largest disclosed position in BSX, valued at $1.2B.
- Did institutional ownership of BSX increase or decrease?
- Across recent 13F filings, tracked investors recorded 12 new positions, 0 increased, 2 reduced, and 0 fully exited BSX.
- What sector is BSX in?
- BOSTON SCIENTIFIC CORP is classified in the Health Care GICS sector, Medical Devices industry.
- Where does this BSX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.